Literature DB >> 26750251

2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport.

Michael L Schulte1, Alexandra B Khodadadi2, Madison L Cuthbertson3, Jarrod A Smith4, H Charles Manning5.   

Abstract

Herein, we report the discovery of 2-amino-4-bis(aryloxybenzyl)aminobutanoic acids as novel inhibitors of ASCT2(SLC1A5)-mediated glutamine accumulation in mammalian cells. Focused library development led to two novel ASCT2 inhibitors that exhibit significantly improved potency compared with prior art in C6 (rat) and HEK293 (human) cells. The potency of leads reported here represents a 40-fold improvement over our most potent, previously reported inhibitor and represents, to our knowledge, the most potent pharmacological inhibitors of ASCT2-mediated glutamine accumulation in live cells. These and other compounds in this novel series exhibit tractable chemical properties for further development as potential therapeutic leads.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ASCT2; Cancer; Glutamine; Metabolism; SLC1A5

Mesh:

Substances:

Year:  2015        PMID: 26750251      PMCID: PMC4727990          DOI: 10.1016/j.bmcl.2015.12.031

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  14 in total

1.  Defining substrate and blocker activity of alanine-serine-cysteine transporter 2 (ASCT2) Ligands with Novel Serine Analogs.

Authors:  Thomas Albers; William Marsiglia; Taniya Thomas; Armanda Gameiro; Christof Grewer
Journal:  Mol Pharmacol       Date:  2011-11-23       Impact factor: 4.436

2.  Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity.

Authors:  Francesca Oppedisano; Marco Catto; Panayiotis A Koutentis; Orazio Nicolotti; Lorena Pochini; Maria Koyioni; Antonellina Introcaso; Sophia S Michaelidou; Angelo Carotti; Cesare Indiveri
Journal:  Toxicol Appl Pharmacol       Date:  2012-09-23       Impact factor: 4.219

3.  Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways.

Authors:  Toshiaki Watanabe; Takashi Kobunai; Yoko Yamamoto; Keiji Matsuda; Soichiro Ishihara; Keijiro Nozawa; Hisae Iinuma; Hiroki Ikeuchi; Kiyoshi Eshima
Journal:  Eur J Cancer       Date:  2011-04-29       Impact factor: 9.162

4.  Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site.

Authors:  C Sean Esslinger; Kimberly A Cybulski; Joseph F Rhoderick
Journal:  Bioorg Med Chem       Date:  2005-02-15       Impact factor: 3.641

Review 5.  Rethinking the Warburg effect with Myc micromanaging glutamine metabolism.

Authors:  Chi V Dang
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

6.  SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.

Authors:  Mohamed Hassanein; Megan D Hoeksema; Masakazu Shiota; Jun Qian; Bradford K Harris; Heidi Chen; Jonathan E Clark; William E Alborn; Rosana Eisenberg; Pierre P Massion
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

Review 7.  MYC-induced cancer cell energy metabolism and therapeutic opportunities.

Authors:  Chi V Dang; Anne Le; Ping Gao
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

8.  In vitro Characterization of a small molecule inhibitor of the alanine serine cysteine transporter -1 (SLC7A10).

Authors:  Jeffrey M Brown; Lisa Hunihan; Margaret M Prack; David G Harden; Joanne Bronson; Carolyn D Dzierba; Robert G Gentles; Adam Hendricson; Rudy Krause; John E Macor; Ryan S Westphal
Journal:  J Neurochem       Date:  2013-12-10       Impact factor: 5.372

9.  Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.

Authors:  Daniela Gaglio; Christian M Metallo; Paulo A Gameiro; Karsten Hiller; Lara Sala Danna; Chiara Balestrieri; Lilia Alberghina; Gregory Stephanopoulos; Ferdinando Chiaradonna
Journal:  Mol Syst Biol       Date:  2011-08-16       Impact factor: 11.429

10.  ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.

Authors:  K Shimizu; K Kaira; Y Tomizawa; N Sunaga; O Kawashima; N Oriuchi; H Tominaga; S Nagamori; Y Kanai; M Yamada; T Oyama; I Takeyoshi
Journal:  Br J Cancer       Date:  2014-03-06       Impact factor: 7.640

View more
  22 in total

1.  Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.

Authors:  Mark A White; Chenchu Lin; Kimal Rajapakshe; Jianrong Dong; Yan Shi; Efrosini Tsouko; Ratna Mukhopadhyay; Diana Jasso; Wajahat Dawood; Cristian Coarfa; Daniel E Frigo
Journal:  Mol Cancer Res       Date:  2017-05-15       Impact factor: 5.852

2.  Radiosynthesis, in vitro and preliminary in vivo evaluation of the novel glutamine derived PET tracers [18F]fluorophenylglutamine and [18F]fluorobiphenylglutamine.

Authors:  Tristan Baguet; Jeroen Verhoeven; Glenn Pauwelyn; Jiyun Hu; Patricia Lambe; Stef De Lombaerde; Sarah Piron; Sam Donche; Benedicte Descamps; Ingeborg Goethals; Christian Vanhove; Filip De Vos; M Hassan Beyzavi
Journal:  Nucl Med Biol       Date:  2020-04-03       Impact factor: 2.408

3.  Ablation of the ASCT2 (SLC1A5) gene encoding a neutral amino acid transporter reveals transporter plasticity and redundancy in cancer cells.

Authors:  Angelika Bröer; Gregory Gauthier-Coles; Farid Rahimi; Michelle van Geldermalsen; Dieter Dorsch; Ansgar Wegener; Jeff Holst; Stefan Bröer
Journal:  J Biol Chem       Date:  2019-01-11       Impact factor: 5.157

Review 4.  Advances and Challenges in Rational Drug Design for SLCs.

Authors:  Rachel-Ann A Garibsingh; Avner Schlessinger
Journal:  Trends Pharmacol Sci       Date:  2019-09-10       Impact factor: 14.819

5.  Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2.

Authors:  Kurnvir Singh; Rose Tanui; Armanda Gameiro; Gilad Eisenberg; Claire Colas; Avner Schlessinger; Christof Grewer
Journal:  Bioorg Med Chem Lett       Date:  2016-12-27       Impact factor: 2.823

Review 6.  Metabolic Imaging of Glutamine in Cancer.

Authors:  Lin Zhu; Karl Ploessl; Rong Zhou; David Mankoff; Hank F Kung
Journal:  J Nucl Med       Date:  2017-02-23       Impact factor: 10.057

Review 7.  Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches.

Authors:  Dominik Awad; Thomas L Pulliam; Chenchu Lin; Sandi R Wilkenfeld; Daniel E Frigo
Journal:  Curr Opin Pharmacol       Date:  2018-03-30       Impact factor: 5.547

8.  Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer.

Authors:  Zhangyi Luo; Jieni Xu; Jingjing Sun; Haozhe Huang; Ziqian Zhang; Weina Ma; Zhuoya Wan; Yangwuyue Liu; Apurva Pardeshi; Song Li
Journal:  Acta Biomater       Date:  2020-01-17       Impact factor: 8.947

9.  Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma.

Authors:  Yongmei Feng; Gaurav Pathria; Susanne Heynen-Genel; Michael Jackson; Brian James; Jun Yin; David A Scott; Ze'ev A Ronai
Journal:  Mol Cancer Ther       Date:  2021-02-25       Impact factor: 6.009

10.  Interaction of the neutral amino acid transporter ASCT2 with basic amino acids.

Authors:  Elias Ndaru; Rachel-Ann A Garibsingh; Laura Zielewicz; Avner Schlessinger; Christof Grewer
Journal:  Biochem J       Date:  2020-04-30       Impact factor: 3.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.